A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium‐Embedded Mesoporous Silica and Chitosan Nanoparticles
ChemistryOpen · 2026-03 · 15 (3)
DOI: 10.1002/open.202500589 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistryOpen, online erschienen am 10.03.2026. Verfasst von Zahra Tavakoli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Curcumin, Silicon Dioxide, Nitriles, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer is the second most common cancer globally, causing ≈396,792 deaths in 2022. Early diagnosis and advanced drug delivery are vital to prevent its progression. This research leverages the anticancer properties of selenium nanoparticles and enzalutamide, a leading prostate cancer drug, by coencapsulating them within mesoporous silica nanoparticles (MSNPs). MSNPs offer advantages for drug delivery, including high surface accessibility and a tunable porous structure. The results indicated that MSNPs synthesized via solvent extraction, yielding a specific surface area of 1017.4 m 2 /g, a pore volume of 0.2531 cm 3 /g, and an average pore size of ≈10 nm, were superior to those obtained by calcination, which yielded a smaller pore size (≈3 nm). Enzalutamide was loaded into these selenium‐embedded MSNPs, achieving a drug loading efficiency of 76.3 ± 0.5%. Separately, curcumin was encapsulated in chitosan nanoparticles with high efficiency (83.2 ± 0.7%). The combined nanosystem enables pH‐responsive, gradual drug release that mimics the tumor microenvironment. MTT assays confirmed the drug‐loaded system exerts significantly stronger, time‐ and concentration‐dependent anticancer effects than the free drug. Furthermore, curcumin plays a vital role in enhancing anticancer efficacy and inducing apoptosis. This research demonstrates that the designed dual‐nanoparticle system is a promising candidate for targeted prostate cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
ORCID-Profile: Zahra Tavakoli, Bijan Ranjbar
Zitieren
APA
Tavakoli, Z., Khajeh, K., & Ranjbar, B. (2026). A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium‐Embedded Mesoporous Silica and Chitosan Nanoparticles. ChemistryOpen, 15(3). https://doi.org/10.1002/open.202500589
Vancouver
Tavakoli Z, Khajeh K, Ranjbar B. A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium‐Embedded Mesoporous Silica and Chitosan Nanoparticles. ChemistryOpen. 2026;15(3). doi:10.1002/open.202500589
BibTeX
@article{Tavakoli2026,
author = {Tavakoli, Zahra and Khajeh, Khosro and Ranjbar, Bijan},
title = {A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium‐Embedded Mesoporous Silica and Chitosan Nanoparticles},
journal = {ChemistryOpen},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/open.202500589}
}
EUVIMED